Research Article

Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes

Table 2

Changes in clinical parameters from baseline with dapagliflozin or empagliflozin.

Dapagliflozin ()Empagliflozin () value‡
Baseline36 months value†Baseline36 months value†

HbA1c, %8.0 (7.6, 8.6)7.0 (6.6, 7.7)<0.0017.9 (7.4, 9.3)7.2 (6.8, 7.9)<0.0010.324
Body weight, kg75 (66, 84)73 (66, 80)<0.00174 (64, 84)71 (62, 80)<0.0010.798
SBP, mmHg142 (131, 155)131 (120, 140)<0.001144 (129,150)132 (120, 140)<0.0010.379
DBP, mmHg80 (74, 89)80 (72, 87)0.22881 (73, 87)77 (68, 82)<0.0010.081
FPG, mg/dL161 (137, 186)136 (117, 156)<0.001167 (134, 188)126 (113, 156)<0.0010.171
ALT, IU/L30 (23, 43)24 (19, 37)<0.00126 (20, 36)23 (19, 30)0.0050.158
Scr, mg/dL0.79 (0.60, 0.95)0.79 (0.61, 0.99)0.2280.90 (0.74, 1.02)0.90 (0.75, 1.07)0.1740.998
eGFR, mL/min/1.73 m289 (74, 105)86 (74, 107)0.89878 (69, 97)82 (70, 95)0.7230.933
CHOL(T), mg/dL150 (128, 173)152 (136, 165)0.913161 (138, 183)153 (131, 179)0.0640.150
Triglyceride, mg/dL127 (97, 177)110 (76, 162)0.031115 (96, 174)107 (74, 160)0.0370.907
LDL-C, mg/dL82 (66, 96)80 (71, 98)0.84690 (72, 111)83 (62, 97)0.0190.059
HDL-C, mg/dL43 (37, 49)42 (37, 53)0.27540 (34, 50)43 (37, 52)0.1940.718

Data are shown as median (IQR). ALT: alanine aminotransferase; CHOT(T): total cholesterol; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FPG: fasting plasma glucose; HbA1c: hemoglobin A1c; HDL-C: high-density lipoprotein-cholesterol level; LDL-C: low density lipoprotein-cholesterol level; SBP: systolic blood pressure; Scr: serum creatinine. †Wilcoxon sign rank test was used to compare of differences within groups measured at baseline and 36 months. ‡Mann–Whitney test was used to compare of differences between groups measured at baseline and 36 months. value <0.05 were considered statistically significant.